In Vitro Infectivity Assessment by Drug Susceptibility Comparison of Recombinant Leishmania major Expressing Enhanced Green Fluorescent Protein or EGFP-Luciferase Fused Genes with Wild-Type Parasite.

Leishmaniasis is a parasitic disease of uncontrolled throughout the world due to lack of effective drugs and vaccines. To accelerate the development of effective drugs, we need a powerful method for rapidly assessing the effectiveness of drugs against intracellular forms of Leishmania in a high throughput testing. reporter gene technology has proven to be an excellent tool for drug screening in vitro. 

The effects of the reporter protein in the Equine Recombinant Proteins parasite infectivity should be identified both in vitro and in vivo. In this study, we first compare the levels of infectivity of recombinant Leishmania major stably expressing enhanced green fluorescent protein (EGFP) alone or EGFP-luciferase (EGFP-LUC) with the wild-type strain. 

Next, we evaluate this parasite sensitivity to amphotericin B (AMB) as the standard drug in the second stage of the parasite, promastigote and amastigote. This comparison was made by MTT and nitric oxide (NO) assay and by measuring the specific signal from the reporter gene such as the intensity of EGFP and luciferase activity. To learn amastigote forms, both B10R and THP-1 macrophage cell lines were infected in the stationary phase and exposed to AMB at the points at different times. 

Our results clearly reveal that the third line has a similar parasite in vitro infectivity levels with comparable levels of parasite induced interferon-γ following NO / lipopolysaccharide induced. Based on our results, we propose a more reporter genes, evaluation faster and more sensitive than the efficiency of the drug.

Brucella abortus Omp19 subcutaneous recombinant protein co-delivered with an antigen-specific antigen response Boost T helper 1 memory and induces protection against parasite challenge.

The discovery of an effective adjuvant for many vaccines, especially those with limited commercial appeal, such as vaccines for diseases associated with poverty, are required.

 In this work, we showed that subcutaneous co-administration of mice with outer membrane proteins U-Omp19 of Brucella spp. plus OVA as an antigen (Ag) enhance Ag-specific T cell proliferation and T helper (Th) 1 immune responses in vitro and Fruit fly Recombinant Proteins in vivo. U-Omp19 treated dendritic cells promote the production of IFN-γ by CD4 (+) T cells and increase proliferation of specific T cell co-administration of U-Omp19 induce the production of Ag specific memory effector T-cell population (T-cells in both CD4 (+) CD44 (high ) CD62L (low)). 

Finally, the co-administration of subcutaneous U-Omp19 with Trypanosoma cruzi Ags confers protection against lethal parasite challenge, reducing parasitaemia and weight loss while increasing the survival of mice. These results indicate that the bacterial protein U-Omp19 when delivered subcutaneously could be a suitable component vaccine formulations against infectious diseases requires a Th1 immune response.